Mounjaro vs Ozempic vs Wegovy vs Zepbound: What's the Difference in 2026?
For people specifically seeking obesity treatment, direct head-to-head evidence favors tirzepatide for average weight loss. However, the "best" medication is not determined by weight loss alone. Diabetes status, cardiovascular or kidney disease, obstructive sleep apnea, side effects, contraindications, access, cost, and treatment goals all matter.
Mounjaro, Ozempic, Wegovy, and Zepbound are among the most discussed medications in modern obesity and metabolic medicine. They are often grouped together as "GLP-1 drugs," but that description is incomplete.
.png "Best Weight Loss Peptides")
Two different molecules are involved:
- Semaglutide: Ozempic and Wegovy
- Tirzepatide: Mounjaro and Zepbound
The brand names can therefore make four medications appear more different than they actually are.
This guide explains what they have in common, where they differ, how much weight loss has been demonstrated in clinical trials, their major indications, side effects, and important developments in 2026.
- Quick comparison
- Mounjaro vs Zepbound: same drug?
- Ozempic vs Wegovy: same drug?
- How do semaglutide and tirzepatide work?
- Which causes more weight loss?
- Which is for diabetes?
- Which is for obesity?
- Cardiovascular and kidney considerations
- Zepbound and sleep apnea
- Side effects and safety
- Dosing and dose escalation
- Cost and access
- Which one is best?
- Compounded semaglutide and tirzepatide
- Frequently asked questions
- Sources and evidence
Mounjaro vs Ozempic vs Wegovy vs Zepbound: Quick Comparison
| Medication | Active ingredient | Drug class | Primary U.S. role | Weight-loss positioning |
|---|---|---|---|---|
| Mounjaro | Tirzepatide | GIP/GLP-1 receptor agonist | Type 2 diabetes | Substantial weight loss, although the brand is primarily the diabetes product |
| Zepbound | Tirzepatide | GIP/GLP-1 receptor agonist | Chronic weight management; also certain adults with obesity and moderate-to-severe OSA | Very high |
| Ozempic | Semaglutide | GLP-1 receptor agonist | Type 2 diabetes | Significant weight loss, although it is not the semaglutide obesity brand |
| Wegovy | Semaglutide | GLP-1 receptor agonist | Chronic weight management and specific cardiovascular-risk indication | Very high |
On a desktop, this remains a conventional five-column comparison table. On phones and other narrow screens, each medication becomes a separate card with labeled fields, making the table much easier to read without sideways scrolling.
The most useful way to understand the four brands is as two medication families:
Mounjaro → primarily type 2 diabetes
Zepbound → chronic weight management and certain obesity-related sleep apnea
Semaglutide family:
Ozempic → primarily type 2 diabetes
Wegovy → chronic weight management and specific cardiovascular-risk reduction
Mounjaro vs Zepbound: Are They the Same Drug?
Yes, they contain the same active ingredient: tirzepatide.
Mounjaro and Zepbound are different branded products built around the same molecule. Their major distinction is their approved indication and associated labeling rather than a different active drug.
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Mechanism | GIP + GLP-1 receptor agonist | GIP + GLP-1 receptor agonist |
| Major U.S. indication | Type 2 diabetes | Chronic weight management |
| Obstructive sleep apnea | Not the Zepbound-branded indication | Approved for certain adults with obesity and moderate-to-severe OSA |
The FDA approved Zepbound for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity.
Zepbound subsequently received an FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
Ozempic vs Wegovy: Are They the Same Drug?
Yes. Both contain semaglutide.
However, they are different branded products with different approved indications and dosing configurations.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Primary positioning | Type 2 diabetes | Chronic weight management |
| Weight management | Weight loss commonly occurs | Specifically indicated for chronic weight management |
| Cardiovascular indication | Specific type 2 diabetes population | Specific adults with established cardiovascular disease and overweight or obesity |
The key point is that same molecule does not mean same brand, indication, dose or labeling.
How Do Semaglutide and Tirzepatide Work?
Semaglutide: GLP-1 receptor agonism
Semaglutide is a long-acting GLP-1 receptor agonist.
GLP-1 is an incretin hormone involved in glucose regulation, appetite signaling and gastrointestinal function. GLP-1 receptor activation can:
- reduce appetite
- increase feelings of fullness
- reduce food intake
- slow gastric emptying
- increase glucose-dependent insulin secretion
- reduce glucagon secretion when glucose levels are elevated
Tirzepatide: GIP + GLP-1
Tirzepatide is a dual incretin receptor agonist. It activates both the GIP receptor and GLP-1 receptor.
This dual mechanism is one reason tirzepatide has demonstrated particularly large effects on both glucose control and body weight.
Which Causes More Weight Loss: Tirzepatide or Semaglutide?
This is one of the most important updates to older comparisons.
We now have randomized head-to-head evidence directly comparing tirzepatide with semaglutide in adults with obesity who did not have type 2 diabetes.
SURMOUNT-5: Direct comparison
In the 72-week SURMOUNT-5 trial, adults with obesity but without type 2 diabetes received tirzepatide or semaglutide.
| Outcome at 72 weeks | Tirzepatide | Semaglutide |
|---|---|---|
| Average weight change | -20.2% | -13.7% |
| Waist circumference | -18.4 cm | -13.0 cm |
| Study population | Adults with obesity without diabetes | Adults with obesity without diabetes |
| Duration | 72 weeks | 72 weeks |
Tirzepatide produced significantly greater reductions in body weight and waist circumference than semaglutide in this direct comparison.
This is more informative than simply comparing weight-loss percentages from separate clinical trials because both treatments were evaluated in the same randomized study population.
Why older comparisons can be misleading
Earlier studies also demonstrated substantial weight loss with both medications. However, comparing results from separate trials can be misleading because the studies may differ in participants, baseline body weight, diabetes status, treatment duration, dose, trial design and background lifestyle intervention.
The STEP 1 trial of semaglutide, for example, reported an average body-weight reduction of approximately 14.9% after 68 weeks in adults with overweight or obesity without diabetes.
SURMOUNT-1 reported mean reductions of approximately 15.0%, 19.5% and 20.9% at 72 weeks with tirzepatide doses of 5 mg, 10 mg and 15 mg, respectively, in its treatment-regimen analysis.
The later SURMOUNT-5 head-to-head trial provides the cleaner comparison between the two molecules for obesity.
Mounjaro vs Ozempic for Type 2 Diabetes
For someone whose primary treatment goal is type 2 diabetes management, Mounjaro and Ozempic are the more relevant brand comparison.
They are different molecules with different receptor activity.
| Feature | Mounjaro | Ozempic |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Receptor activity | GIP + GLP-1 | GLP-1 |
| Type 2 diabetes | Yes | Yes |
| Weight reduction | Substantial | Substantial |
| Cardiovascular evidence | Evidence continues to evolve | Established cardiovascular outcome evidence in specific diabetes populations |
The diabetes decision should therefore not be based solely on which drug produces the largest weight loss.
Cardiovascular risk, kidney disease, glycemic targets, hypoglycemia risk, tolerability, other medications and patient preferences may all influence treatment selection.
Wegovy vs Zepbound for Weight Loss
For chronic weight management, the more direct comparison is:
Wegovy = semaglutide
Zepbound = tirzepatide
The SURMOUNT-5 head-to-head trial strongly favors tirzepatide for average weight reduction over 72 weeks in adults with obesity without type 2 diabetes.
If the question is strictly "Which produced more average weight loss in a direct head-to-head obesity trial?" the evidence favors tirzepatide.
If the question is "Which medication should this particular person use?" there is no universal answer.
Cardiovascular and Kidney Considerations
These medications should not be evaluated solely as cosmetic weight-loss drugs.
Obesity and type 2 diabetes are major risk factors for cardiovascular and kidney disease, and some incretin-based therapies have demonstrated benefits beyond body weight.
Semaglutide
Wegovy has an FDA indication to reduce the risk of major adverse cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity.
Ozempic has cardiovascular outcome evidence in people with type 2 diabetes and established cardiovascular disease. Its labeling also includes kidney-outcome data for specific people with type 2 diabetes and chronic kidney disease.
Tirzepatide
Tirzepatide has demonstrated substantial effects on body weight and glucose control. Its cardiovascular-outcome evidence continues to develop.
This distinction matters because a patient choosing treatment for obesity, diabetes, cardiovascular-risk reduction or kidney protection may have different priorities.
Zepbound and Obstructive Sleep Apnea
One major development missing from many older GLP-1 comparison articles is the FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
Clinical trials demonstrated significant reductions in sleep-apnea severity in adults with obesity treated with tirzepatide compared with placebo, alongside substantial weight loss.
This expands the clinical relevance of tirzepatide beyond weight reduction and glucose control.
Side Effects: Mounjaro, Zepbound, Ozempic and Wegovy
Because these medications affect gastrointestinal and appetite pathways, many of their adverse effects involve the digestive system.
| Common issue | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | Common | Common |
| Diarrhea | Common | Common |
| Vomiting | Can occur | Can occur |
| Constipation | Can occur | Can occur |
| Abdominal discomfort | Can occur | Can occur |
| Reduced appetite | Expected pharmacologic effect | Expected pharmacologic effect |
Gastrointestinal adverse events are particularly common during dose escalation and are often the reason clinicians increase doses gradually.
Important safety considerations
Depending on the specific product and patient, prescribing information contains important warnings and contraindications involving:
- thyroid C-cell tumors
- pancreatitis
- gallbladder disease
- dehydration and kidney injury
- severe gastrointestinal reactions
- hypoglycemia when combined with insulin or certain insulin secretagogues
- diabetic retinopathy complications
- hypersensitivity reactions
- potential aspiration risk during anesthesia or deep sedation
Wegovy prescribing information includes a boxed warning concerning thyroid C-cell tumors based on rodent findings and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
How Are These Medications Dosed?
All four products are associated with once-weekly administration, although the exact starting dose, escalation schedule and maximum dose depend on the specific product and indication.
The general treatment principle is:
Gradual dose escalation is designed in part to improve gastrointestinal tolerability.
Patients should not independently accelerate dose increases because they want faster weight loss.
Cost, Insurance and Access
The financial picture varies considerably by country and patient.
Actual out-of-pocket costs can depend on:
- country
- insurance coverage
- employer health benefits
- medical indication
- manufacturer programs
- pharmacy pricing
- availability
- local regulatory rules
A medication that produces greater average weight loss may not be the most practical choice if a patient cannot consistently access or afford it.
This is especially important because obesity treatment is generally considered a long-term management strategy rather than a short course of medication.
Which Is Best: Mounjaro, Ozempic, Wegovy or Zepbound?
There is no single "best" medication for everyone.
A better approach is to match the medication to the clinical objective.
| Primary goal | Potentially relevant options | Key consideration |
|---|---|---|
| Type 2 diabetes | Mounjaro, Ozempic | Compare glucose control, weight effects, cardiovascular and kidney considerations, tolerability and access |
| Chronic obesity treatment | Zepbound, Wegovy | Tirzepatide produced greater average weight loss than semaglutide in SURMOUNT-5 |
| Obesity + moderate/severe OSA | Zepbound | FDA-approved indication for qualifying adults with obesity |
| Established cardiovascular disease + overweight/obesity | Wegovy may be particularly relevant | FDA cardiovascular-risk reduction indication applies to specific patients |
| Type 2 diabetes + CKD | Ozempic may be relevant | Consider the kidney-outcome evidence and the patient's overall clinical profile |
What About "Ozempic for Weight Loss"?
This is one of the most common sources of confusion online.
Ozempic contains semaglutide and can cause substantial weight loss, but Wegovy is the semaglutide product specifically developed and approved for chronic weight management.
Likewise, Mounjaro contains tirzepatide and can produce substantial weight loss, while Zepbound is the tirzepatide product specifically approved for chronic weight management.
Therefore:
- Ozempic vs Wegovy is largely a semaglutide product and indication comparison.
- Mounjaro vs Zepbound is largely a tirzepatide product and indication comparison.
- Wegovy vs Zepbound is the more relevant comparison when the primary question is obesity treatment.
- Ozempic vs Mounjaro is the more relevant comparison when the primary question is type 2 diabetes.
2026 Update: The Semaglutide and Tirzepatide Landscape Is Changing
Older articles often describe Wegovy, Ozempic, Mounjaro and Zepbound as though the treatment landscape is static. It is not.
Regulatory approvals, formulations, dosing options, clinical indications and cardiovascular or metabolic outcome data continue to evolve.
This is particularly important for patients researching these medications online because a comparison published several years ago may no longer reflect current prescribing information.
The most important evidence update for weight loss remains the direct SURMOUNT-5 comparison between tirzepatide and semaglutide.
What About Compounded Semaglutide and Tirzepatide?
Consumers should distinguish FDA-approved branded medications from compounded products.
Compounded drugs are not automatically equivalent to FDA-approved products in terms of regulatory review, manufacturing oversight, labeling or demonstrated clinical evidence.
The FDA has warned companies against misleading claims that compounded semaglutide or tirzepatide products are FDA-approved.
Bottom Line
Mounjaro, Ozempic, Wegovy and Zepbound belong to the same broader era of incretin-based metabolic medicine, but they are not interchangeable in terms of indication and evidence.
The simplest way to remember the four brands is:
Zepbound = tirzepatide = obesity/weight management + certain obesity-related OSA
Ozempic = semaglutide = primarily diabetes
Wegovy = semaglutide = obesity/weight management + specific cardiovascular indication
For weight loss specifically, the most important evidence update is the SURMOUNT-5 head-to-head trial. At 72 weeks, tirzepatide produced greater average weight loss than semaglutide in adults with obesity without type 2 diabetes.
But "more weight loss" should not automatically be translated into "best drug for everyone."
The appropriate decision depends on the patient's diagnosis, treatment objective, cardiovascular and kidney profile, sleep apnea status, tolerability, other medications, contraindications, cost and access.
Frequently Asked Questions
Is Mounjaro the same as Zepbound?
Mounjaro and Zepbound contain the same active ingredient, tirzepatide. Mounjaro is primarily positioned for type 2 diabetes, while Zepbound is approved for chronic weight management and certain adults with obesity and moderate-to-severe obstructive sleep apnea.
Is Ozempic the same as Wegovy?
Ozempic and Wegovy both contain semaglutide, but they are different branded products with different FDA-approved indications and dosing configurations.
Which is stronger for weight loss, Wegovy or Zepbound?
In the 72-week SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide. Tirzepatide is the active ingredient in Zepbound, while semaglutide is the active ingredient in Wegovy.
Which is better for diabetes, Ozempic or Mounjaro?
There is no universal winner. Tirzepatide can produce substantial glucose and weight improvements, while semaglutide has established cardiovascular and kidney outcome evidence in specific type 2 diabetes populations. The appropriate choice depends on the patient's medical profile and treatment goals.
Can Ozempic be used for weight loss?
Semaglutide can cause substantial weight loss. However, Wegovy is the semaglutide product specifically indicated for chronic weight management in qualifying patients, while Ozempic is primarily a type 2 diabetes product.
Can Mounjaro be used for weight loss?
Tirzepatide causes substantial weight loss, but Zepbound is the tirzepatide product specifically approved for chronic weight management.
Does tirzepatide work better than semaglutide?
For weight reduction in adults with obesity without type 2 diabetes, direct head-to-head evidence found that tirzepatide produced greater average weight loss than semaglutide at 72 weeks. That does not establish that tirzepatide is preferable for every clinical situation.
What are the most common side effects?
Common adverse effects include gastrointestinal symptoms such as nausea, diarrhea, vomiting, constipation and abdominal discomfort. Product-specific warnings and contraindications should be reviewed before treatment.
Does Zepbound treat sleep apnea?
Yes. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity.
Are compounded semaglutide and tirzepatide the same as Ozempic, Wegovy, Mounjaro or Zepbound?
Not necessarily. Compounded products can contain the same active ingredient but have a different regulatory status and manufacturing framework. Consumers should not assume that a compounded medication is FDA-approved simply because it contains semaglutide or tirzepatide.
Sources and Evidence
FDA: Zepbound approval for chronic weight management
FDA: Zepbound approval for obstructive sleep apnea
FDA: Wegovy prescribing information
FDA: Zepbound prescribing information
NEJM: SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
NEJM: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
NEJM: SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity
Comments
Post a Comment